The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Acute Lymphoblastic Leukemia (ALL) in Adults: In Detail
Acute Lymphoblastic Leukemia (ALL) in Children and Teens: In Detail
- No updates
Acute Myeloid Leukemia (AML) in Adults: In Detail
Acute Myeloid Leukemia in Children and Teens: In Detail
- In May 2026, the Food and Drug Administration (FDA) approved decitabine and cedazuridine (Inqovi®) in combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
- In November 2025, the Food and Drug Administration (FDA) approved ziftomenib (Komzifti™) to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.
- In November 2025, the Food and Drug Administration (FDA) expanded the indication of Revumenib (Revuforj®) to include the treatment of adults and children 1 year and older with acute myeloid leukemia with a nucleophosmin 1 (NPM1) mutation whose disease has come back or has not improved after previous treatment(s) and who have no other satisfactory treatment options.
Chronic Lymphocytic Leukemia: In Detail
- In October 2026, the Food and Drug Administration (FDA) expanded the indication of pirtobrutinib (Jaypirca®) to include the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion.
Chronic Myeloid Leukemia: In Detail
No Updates
Blood Cancer United resources
Find free, specialized guidance and information for every type of blood cancer, request financial support, find emotional support, and connect with other members of the blood cancer community.
